Aesyra's Smart Device Slashes Teeth Grinding by 60%

LAUSANNE, Switzerland – January 26, 2026 – Millions who suffer from the painful, often subconscious habit of grinding their teeth at night may soon have a new, high-tech solution. Swiss medtech company Aesyra SA has announced compelling results from a clinical study of its intelligent oral appliance, AesyBite™ Active, which demonstrated a remarkable 60.6% reduction in sleep bruxism activity.

The device, which uses gentle biofeedback to actively curb grinding and clenching, represents a significant potential leap forward from the passive nightguards that currently dominate the market. The successful trial moves the EPFL spin-off one step closer to bringing its digital therapeutic to a global market, with regulatory submission to the U.S. Food and Drug Administration (FDA) already underway.

"These results represent a major milestone for Aesyra," said Marco Letizia, co-founder and CEO of Aesyra SA, in a statement. "Demonstrating a consistent and robust reduction in sleep bruxism activity, together with an excellent safety profile, strongly supports the clinical value of AesyBite Active and its potential to change how sleep bruxism is treated."

Beyond the Passive Nightguard

Sleep bruxism is a widespread condition, affecting up to 30% of adults. It involves the involuntary clenching or grinding of teeth during sleep, leading to a host of debilitating symptoms including jaw pain, chronic headaches, muscle tension, and significant damage to teeth and dental work. According to a 2021 survey by the American Dental Association's Health Policy Institute, over 70% of dentists reported an increase in patients with signs of teeth grinding, a trend many link to rising stress levels.

For decades, the standard treatment has been the occlusal splint, or nightguard. These custom-fitted plastic devices act as a protective barrier, preventing tooth-on-tooth wear and reducing grinding sounds. While effective at mitigating damage, they are a passive solution; they do not address the underlying neuromuscular activity that causes the grinding in the first place. Some softer, over-the-counter versions can even inadvertently encourage more clenching behavior.

Other treatments, such as behavioral therapy, medication, or Botox injections into the jaw muscles, have shown limited or inconsistent efficacy and can come with undesirable side effects, leaving a significant unmet need for a treatment that is both effective and safe for long-term use.

The Science of Smart Biofeedback

Aesyra’s AesyBite™ Active is engineered to be more than just a protective shield. The customized oral appliance is embedded with proprietary sensors that continuously monitor for the muscle activity associated with grinding and clenching. When bruxism is detected, the device delivers a subtle biofeedback signal, prompting the jaw muscles to relax without disturbing the user's sleep.

The recent clinical investigation (NCT06153810), which involved 26 adult patients with confirmed sleep bruxism, put this technology to the test. The results were statistically significant and clinically meaningful. The primary endpoint showed a 60.6% reduction in the total duration of sleep bruxism per hour compared to the patients' baseline levels.

Furthermore, the study reported significant improvements across multiple secondary measures, including a decrease in the number and intensity of grinding episodes. Crucially, the device had no negative impact on overall sleep duration, and no adverse events were reported. Patient-reported outcomes also showed a progressive reduction in orofacial pain and improved comfort over time, suggesting high patient acceptance for nightly use.

“The magnitude and consistency of the effect observed in this investigation are particularly encouraging,” noted Prof. Marcello Maddalone of the University of Milano-Bicocca, who served as the study's Principal Investigator. “The data support AesyBite Active as an effective and well-tolerated therapeutic option for patients suffering from sleep bruxism.”

From Lab to Market

The positive clinical data provides a strong tailwind for Aesyra’s commercial ambitions. The company, a spin-off from the prestigious Swiss Federal Institute of Technology Lausanne (EPFL), has initiated its submission to the FDA, targeting regulatory approval in the United States for 2026. Approval in Europe is planned to follow.

Aesyra is well-positioned to navigate this capital-intensive process. In late 2023, the company secured $3 million in seed funding in a round led by Supermoon Capital, the world's first fund dedicated to sleep technology, and deep tech investor Creadd Ventures. This financial backing is aimed squarely at finalizing development and launching the AesyBite® product line.

With regulatory milestones in sight, Aesyra is preparing its go-to-market strategy for 2026, which includes leveraging existing partnerships and forging new ones to reach a wide patient base. The company’s vision extends beyond a single product, aiming to build a comprehensive platform for diagnosing and treating sleep-related oral disorders. This includes AesyBite™ Custom, a next-generation solution that will utilize intraoral 3D scans and additive manufacturing to create highly personalized devices, further enhancing comfort and efficacy for patients.

This platform approach signals a broader shift in dental and sleep medicine toward smart, data-driven digital therapeutics that offer personalized and proactive care. By actively intervening to reduce harmful grinding rather than just absorbing the damage, Aesyra's technology could soon offer millions a quieter, more restorative, and pain-free night's sleep.